FDA grants Orphan Drug Designation to Poseida's P-BCMA-ALLO1 for multiple myeloma treatment.

Poseida Therapeutics announces FDA Orphan Drug Designation granted to P-BCMA-ALLO1 for multiple myeloma treatment. P-BCMA-ALLO1, a BCMA-targeted allogeneic T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate, is being investigated in partnership with Roche for relapsed/refractory multiple myeloma (RRMM). The FDA designation highlights the high unmet medical need for an off-the-shelf allogeneic CAR-T therapy.

March 13, 2024
4 Articles

Further Reading